It targets protein tyrosine kinase 7 (PTK7), which has shown to be consistently and highly expressed on the cell surface of multiple adult and pediatric cancers, including platinum-resistant ovarian cancer, triple negative breast cancer, non-small cell lung cancer, neuroblastoma and osteosarcoma. DAY301 has been designed to maximize the therapeutic index and overcome limitations of previous-generation ADCs.